Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-261-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Protocol to the Euro-Mediterranean Agreement establishing an association between the EC and Israel on Conformity Assessment and Acceptance of Industrial Products (CAA) (debate)2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20121023.17.2-261-000"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-262-0002
lpv:speaker	lp:Laima Liucija Andrikienė2
lpv:spokenAs	member; DROI (2012-01-19--2014-06-30)3 substitute; Delegation to the EU-Mexico Joint Parliamentary Committee (2009-10-12--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 member; Delegation for relations with Belarus (2009-09-16--2014-06-30)3 member; INTA (2012-01-19--2014-06-30)3 substitute; AFET (2012-01-19--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-12--2014-06-30)3 unknown; Tėvynės sąjunga - Lietuvos krikščionys demokratai (2009-07-14--2014-06-30)3
lpv:translated text	"Madam President, the PPE Group is in favour of the ACAA and we look forward to the vote in order to give our consent to this important agreement between the EU and Israel. After a deliberation of more than two and a half years, we are finally having this discussion in the plenary session on ACAA. I am happy that there has been enough common sense among our colleagues in the INTA Committee to vote in favour of this agreement, which is good for both the EU and Israel and is part of the EU Association Agreement. Israel is the first country in the Mediterranean Region to achieve the basic conditions that enable it to reach an ACAA with the EU. The ACAA, together with the additional protocol on pharmaceutical products, aims at facilitating market access by eliminating technical barriers to trade in industrial products. In order to make the framework of the ACAA operational, it has to be implemented into specific sectors, practices and regulations. As we know, once adopted, the ACAA would cover mutual recognition of regulatory and verification procedures for pharmaceutical products in the EU and Israel. Such mutual recognition would certainly benefit European consumers and they would get quicker access to Israeli pharmaceutical products, as there would no longer be a need for a second testing in the EU – something that normally takes from one to three years. Colleagues, it should be mentioned that it took Israel more than six years to adopt the necessary standards in the field of good manufacturing practice for pharmaceutical products. In other words, in order to conclude this agreement, and the additional protocol, Israel had to substantially approximate its regulatory framework on pharmaceutical products to that of the EU. So we are spreading our acquis communautaire to Israel, with a spill-over effect to other areas as well. In other words, it is in the EU’s interest to get Israel’s legislation and standards closer to the EU’s. I would, therefore, like to encourage my colleagues to give our consent to the ACAA later today."@en1
lpv:unclassifiedMetadata	"(The speaker agreed to take a blue-card question under Rule 149(8))"1 "Laima Liucija Andrikienė,"1 "on behalf of the PPE Group"1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph